Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) had its price target lowered by analysts at Raymond James from $44.00 to $23.00.
Intercept Pharmaceuticals, Inc. (ICPT)
Last intercept pharmaceuticals, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.interceptpharma.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ICPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICPT alerts
High impacting Intercept Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ICPT
News
- Intercept Announces First Patient Dosed In Phase 2 Study Of OCA And Bezafibrate For The Treatment Of Primary Biliary Cholangitis [TheStreet.com]TheStreet.com
- Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary CholangitisGlobeNewswire
- Intercept Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ICPT/price-target/">NASDAQ: ICPT</a>) had its price target raised by analysts at B. Riley from $30.00 to $32.00.MarketBeat
- Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire
ICPT
Earnings
- 5/6/22 - Beat
ICPT
Sec Filings
- 5/20/22 - Form DEFA14A
- 5/17/22 - Form 4
- 5/13/22 - Form DEFA14A
- ICPT's page on the SEC website